Intelligence / MOTS-c

MOTS-c

Prescription Only
Mitochondrial Peptide
Schedule
S4
Prescription Only
Enforcement
Monitoring
Medium Risk
Providers
4
Access: Emerging
Key Facts
Schedule 4 - Prescription Only
Mitochondrial-derived peptide
4 identified Australian providers
Limited prescriber familiarity
Growing interest in Australian market

Overview

MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA gene. It is an emerging peptide in the Australian market with limited prescriber familiarity. Not yet widely compounded, but interest is growing.

Australian Scheduling

Schedule 4 (Prescription Only). TGA is monitoring this peptide as its use grows. Limited compounding infrastructure currently in place.

Access Pathway

Available through a small number of telehealth providers. 4 identified Australian providers. Prescriber familiarity is limited, and not all compounding pharmacies have established formulations.

Regulatory Notice

For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.

Are You a Practitioner?

List your clinic for free and reach patients actively searching for legal peptide access in Australia.